MedKoo Cat#: 584255 | Name: Bremazocine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bremazocineis a potent, log-acting opiate kappa-agonist & centrally acting analgesic.

Chemical Structure

Bremazocine
Bremazocine
CAS#75684-07-0

Theoretical Analysis

MedKoo Cat#: 584255

Name: Bremazocine

CAS#: 75684-07-0

Chemical Formula: C20H29NO2

Exact Mass: 315.2198

Molecular Weight: 315.46

Elemental Analysis: C, 76.15; H, 9.27; N, 4.44; O, 10.14

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Bremazocine
IUPAC/Chemical Name
2,6-Methano-3-benzazocin-8-ol, 6-ethyl-1,2,3,4,5,6-hexahydro-3-((1-hydroxycyclopropyl)methyl)-11,11-dimethyl-, (2R)-
InChi Key
ZDXGFIXMPOUDFF-DIAVIDTQSA-N
InChi Code
InChI=1S/C20H29NO2/c1-4-20-9-10-21(13-19(23)7-8-19)17(18(20,2)3)11-14-5-6-15(22)12-16(14)20/h5-6,12,17,22-23H,4,7-11,13H2,1-3H3/t17-,20?/m1/s1
SMILES Code
OC1=CC=C2C(C3(CC)CCN(CC4(O)CC4)[C@](C3(C)C)([H])C2)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 315.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Petrillo P, Gambino MC, Tavani A. Bremazocine induces antinociception, but prevents opioid-induced constipation and catatonia in rats and precipitates withdrawal in morphine-dependent rats. Life Sci. 1984 Aug 27;35(9):917-27. PubMed PMID: 6381949. 2: Simonin F, Slowe S, Becker JA, Matthes HW, Filliol D, Chluba J, Kitchen I, Kieffer BL. Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice. Eur J Pharmacol. 2001 Mar 2;414(2-3):189-95. PubMed PMID: 11239918. 3: Dortch-Carnes J, Potter DE. Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties. CNS Drug Rev. 2005 Summer;11(2):195-212. Review. PubMed PMID: 16007240. 4: Shearman GT, Stenfors C. Bremazocine-induced backwards walking behavior in rats is mediated via opioid kappa receptors. Pharmacol Biochem Behav. 1986 Apr;24(4):861-3. PubMed PMID: 3012599. 5: Cosgrove KP, Carroll ME. Differential effects of bremazocine on oral phencyclidine (PCP) self-administration in male and female rhesus monkeys. Exp Clin Psychopharmacol. 2004 May;12(2):111-7. PubMed PMID: 15122955. 6: Castellano C, Pavone F. Effects of bremazocine on passive avoidance behaviour in mice. Arch Int Pharmacodyn Ther. 1986 Oct;283(2):199-208. PubMed PMID: 3789883. 7: Nestby P, Schoffelmeer AN, Homberg JR, Wardeh G, De Vries TJ, Mulder AH, Vanderschuren LJ. Bremazocine reduces unrestricted free-choice ethanol self-administration in rats without affecting sucrose preference. Psychopharmacology (Berl). 1999 Mar;142(3):309-17. PubMed PMID: 10208324. 8: Russell KR, Wang DR, Potter DE. Modulation of ocular hydrodynamics and iris function by bremazocine, a kappa opioid receptor agonist. Exp Eye Res. 2000 May;70(5):675-82. PubMed PMID: 10870526. 9: Bianchi G. Antidiuretic effect of bremazocine and U-50,488 in rats after alpha 2-adrenoceptor blockade. J Pharm Pharmacol. 1991 Mar;43(3):212-6. PubMed PMID: 1675283. 10: Freye E, Hartung E, Schenk GK. Bremazocine: an opiate that induces sedation and analgesia without respiratory depression. Anesth Analg. 1983 May;62(5):483-8. PubMed PMID: 6301311. 11: Amarante LH, Duarte ID. The kappa-opioid agonist (+/-)-bremazocine elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic GMP pathway. Eur J Pharmacol. 2002 Nov 1;454(1):19-23. PubMed PMID: 12409000. 12: Potter DE, Russell KR, Manhiani M. Bremazocine increases C-type natriuretic peptide levels in aqueous humor and enhances outflow facility. J Pharmacol Exp Ther. 2004 May;309(2):548-53. Epub 2004 Jan 23. PubMed PMID: 14742737. 13: Vanderschuren LJ, Schoffelmeer AN, Wardeh G, De Vries TJ. Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine. Psychopharmacology (Berl). 2000 May;150(1):35-44. PubMed PMID: 10867974. 14: Horan PJ, de Costa BR, Rice K, Haaseth RC, Hruby VJ, Porreca F. Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: further functional evidence of opioid kappa receptor multiplicity in the mouse. J Pharmacol Exp Ther. 1993 Aug;266(2):926-33. PubMed PMID: 8394923. 15: Negus SS, Morgan D, Cook CD, Picker MJ. Effects of the delta opioid against BW373U86 in pigeons trained to discriminate fentanyl, bremazocine and water in a three-choice drug discrimination procedure. Psychopharmacology (Berl). 1996 Aug;126(3):199-205. PubMed PMID: 8876019. 16: Horan P, de Costa BR, Rice KC, Porreca F. Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice. J Pharmacol Exp Ther. 1991 Jun;257(3):1154-61. PubMed PMID: 1646325. 17: Castellano C, Pavone F. Effects of bremazocine on locomotor activity in DBA/2 and C57BL/6 mice. Arch Int Pharmacodyn Ther. 1985 Nov;278(1):45-52. PubMed PMID: 4096608. 18: Amarante LH, Alves DP, Duarte ID. Study of the involvement of K+ channels in the peripheral antinociception of the kappa-opioid receptor agonist bremazocine. Eur J Pharmacol. 2004 Jun 28;494(2-3):155-60. PubMed PMID: 15212969. 19: Rasmussen CA, Gabelt BT, Kaufman PL. Aqueous humor dynamics in monkeys in response to the kappa opioid agonist bremazocine. Trans Am Ophthalmol Soc. 2007;105:225-38; discussion 238-9. PubMed PMID: 18427613; PubMed Central PMCID: PMC2258115. 20: Li Q, Kim SK, Goddard WA 3rd, Chen G, Tan H. Predicted structures for kappa opioid G-protein coupled receptor bound to selective agonists. J Chem Inf Model. 2015 Mar 23;55(3):614-27. doi: 10.1021/ci500523z. Epub 2015 Feb 17. PubMed PMID: 25642595.